EDX Medical Founder Sir Christopher Evans to present at London investor event

EDX Medical Group plc

EDX Medical Group plc (LON:EDX), which develops and supplies innovative digital diagnostic products and services to improve the early detection and treatment of major diseases, has announced that Professor Sir Christopher Evans OBE, Founder & Chief Scientific Officer of the Company, will attend and present at the Yellowstone Advisory Private Investor Evening on Wednesday 11 November 2026.

The event will be held at the London offices of SEC Newgate. Investors can register for the event here: https://www.yellowstoneadvisory.com/events

Any questions about the evening should be emailed to [email protected].

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

EDX Medical Founder Sir Christopher Evans to present at London investor event

EDX Medical Group has announced that Founder and Chief Scientific Officer Professor Sir Christopher Evans OBE will present at...

EDX Medical appoints biotech industry veteran Professor Michael Owen as Chairman

EDX Medical Group has appointed Professor Michael Owen as non-executive Chairman with immediate effect, succeeding Jason Holt. The former...

EDX Medical expands employee health screening with wider disease testing

EDX Medical is expanding employee health screening with tests designed to identify hundreds of diseases from one or two...

Scottish Prostate Cancer Initiative targets 25,000 tests by year end

The initiative has tested more than 16,000 men since March and is targeting 25,000 tests by the end of...

EDX Medical signs three-year employee health screening deal with Arnold Clark Group

EDX Medical has entered a three-year agreement to provide health and wellbeing screening to Arnold Clark Group employees across...

EDX Medical reports diagnostic milestones and £330,000 revenue for FY2026

EDX Medical’s annual results highlight new cancer testing services, major diagnostic partnerships and £5.5 million in funding, alongside a...

Search